2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Cell Expansion, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Women’s Health, Adverse Events, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bone Marrow Failure Syndromes, Hemoglobinopathies, Sickle Cell Disease, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

4262 Lessons learned from unsupervised clustering of laboratory biomarkers in diffuse alveolar hemorrhage after allogeneic hematopoietic stem cell transplantation to identify distinct phenotypes for early mortality risk stratification: A national representative study

Dong Liang, Zhuo-Yu An, MD2, Qiu-Sha Huang, MD3, Jin Wu4, Hai-Xia Fu, MD5, Peng Zhao6, Dingming Wan7, Shun-Qing Wang8, Sanbing Wang, MD9, Kehong Bi10, Ying Lu11, Xiao-Dong Mo, MD12, Yuanyuan Zhang13, Yifei Cheng14, yuqian Sun15, Chen-hua Yan16, Yuhong Chen17, Meng Lv18, Yu Wang19, Ying-Jun Chang20, Xiangyu Zhao, MD, PhD21, Lanping Xu, MD22, Xiaojun Huang, MD,PhD23, Xiaohui Zhang, MD24
1 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
2 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
3 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
4 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
5 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
6 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
7 Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
8 Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China
9 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, China
10 Department of Hematology, School of First Affiliated Hospital of Shandong First Medical University, Shandong Province Qianfoshan Hospital, Jinan, China
11 Department of Haematology, Affiliated People's Hospital of Ningbo University, Ningbo, China
12 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
13 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
14 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
15 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
16 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
17 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
18 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
19 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
20 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
21 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
22 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
23 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
24 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
Introduction

Diffuse alveolar hemorrhage (DAH) is one of the most devastating complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT), with mortality rates of 80–100% despite current therapies. Given that many patients die within 14 days of diagnosis, early risk stratification is urgently needed. However, the biological heterogeneity underlying post-transplant DAH remains poorly understood, limiting prognostic assessment and individualized management. In this nationally representative cohort, we used unsupervised clustering of laboratory biomarkers to define distinct DAH phenotypes and investigate their associations with early mortality after allo-HSCT.

Methods

This multicenter study included 204 patients with DAH after allo-HSCT treated at the Peking University Institute of Hematology and five additional transplant centers across China between January 2009 and September 2025, representing the largest Chinese cohort of post-transplant DAH. Unsupervised Gaussian mixture modeling was performed using nine routinely available laboratory variables reflecting systemic inflammation, coagulation and fibrinolysis, and tissue or organ injury. The optimal number of clusters was selected using the Bayesian information criterion, and cluster stability was assessed by bootstrap resampling with Jaccard coefficients. Clinical characteristics and survival outcomes were compared between the phenotypes. Multivariable logistic regression was used to evaluate the association between phenotypes and 14-day mortality after adjustment for age ≥35 years, grade III–IV aGVHD, extensive chronic GVHD, underlying disease risk, and respiratory failure.

Results

DAH occurred in 2.5% of allo-HSCT recipients across the participating centers. During the available follow-up period, 84.3% of the patients died, including 55.9% who died within 14 days after the DAH diagnosis. Unsupervised clustering revealed two distinct laboratory phenotypes: a lower-inflammation/lower-injury phenotype comprising 165 patients and a hyperinflammatory organ injury phenotype comprising 39 patients. Compared with the lower inflammation/lower injury phenotype, the hyperinflammatory organ injury phenotype was characterized by higher levels of C-reactive protein, D-dimer, international normalized ratio, lactate dehydrogenase, total bilirubin, aspartate aminotransferase, and alkaline phosphatase, together with lower fibrinogen and hemoglobin levels.

The median survival duration after DAH diagnosis was 13 days (95% CI, 11–NR) in the lower-inflammation/lower-injury phenotype group and 3 days (95% CI, 1–9) in the hyperinflammatory organ injury phenotype group. The corresponding 14-day survival rates were 48.1% (95% CI, 41.0%–56.4%) and 25.6% (95% CI, 15.0%–43.8%), respectively, with a significant difference between the two phenotypes (P<0.01). Among patients with acute leukemia, the median survival was 3 days (95% CI, 1–9) for those with the hyperinflammatory organ injury phenotype and 14 days (95% CI, 11–NR) for those with the lower inflammation/lower injury phenotype. Similarly, among patients with other underlying diseases, the median survival times were 3 days (95% CI, 1–NR) and 13 days (95% CI, 9–NR), respectively. Significant survival differences between the two phenotypes were observed in both disease subgroups, supporting the consistency of their prognostic separation across underlying disease categories.

After adjustment for established clinical prognostic factors, the hyperinflammatory organ injury phenotype remained independently associated with increased 14-day mortality (OR, 2.74; 95% CI, 1.15–6.57; P=0.023). Through bootstrap resampling, the identified phenotypes demonstrated high stability for the lower-inflammation/lower-injury phenotype and moderate-to-good stability for the hyperinflammatory organ injury phenotype, with mean Jaccard coefficients of 0.93 and 0.76, respectively.

Conclusions

Unsupervised Gaussian mixture modeling revealed two clinically interpretable laboratory phenotypes with distinct prognostic profiles among patients with DAH after allo-HSCT. The hyperinflammatory organ injury phenotype was independently associated with increased early mortality, whereas the lower inflammation/lower injury phenotype was associated with more favorable outcomes. These findings highlight the biological heterogeneity of post-transplant DAH and may support early risk stratification and intensified clinical monitoring.

Dong Liang: No relevant conflicts of interest to declare.